Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Segment Performance
BIO logo

Bio-Rad's Sales Drop 3.9% as Diagnostics Offsets Life Science Slump

BIO10-KFiling Date: 2/14/2025
Bio-Rad Laboratories, Inc.
Description

What this story covers

Bio-Rad's 2024 net sales fell 3.9% to $2.57B, driven by 12.8% Life Science decline offset by 3.3% Clinical Diagnostics growth. Gross margins rose to 53.7%; Sartorius investment caused $2.66B fair value loss, widening net loss to $1.84B. Strong $455M operating cash supports liquidity amid risks.

Story snapshot

CompanyBio-Rad Laboratories, Inc.
TickerBIO
VariantStandard detailed
Duration12:17
Filing type10-K
PeriodAnnual 2024
IndustryHealthcare & Pharmaceuticals
Accession0000012208-25-000007

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in